The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization

Liver Cancer

Volumn 6, Issue 3, 2017, Pages 227-235

  Arizumi, Tadaaki ^a   Ueshima, Kazuomi ^a   Iwanishi, Mina ^a   Minami, Tomohiro ^a   Chishina, Hirokazu ^a   Kono, Masashi ^a   Takita, Masahiro ^a   Yada, Norihisa ^a   Hagiwara, Satoru ^a   Minami, Yasunori ^a   Ida, Hiroshi ^a   Komeda, Yoriaki ^a   Takenaka, Mamoru ^a   Sakurai, Toshiharu ^a   Watanabe, Tomohiro ^a   Nishida, Naoshi ^a   Kudo, Masatoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; Kinki criteria; Overall survival; Time to progression after transarterial chemoembolization; Transarterial chemoembolization

Indexed keywords

CISPLATIN; EPIRUBICIN; GELATIN; GELFOAM; IODINATED POPPYSEED OIL; MIRIPLATIN;

AGED; ARTICLE; CANCER STAGING; CHEMOEMBOLIZATION; EMBOLIC PARTICLE; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PRIORITY JOURNAL; TIME TO PROGRESSION;

EID: 85039162797     PISSN: 22351795     EISSN: 16645553     Source Type: Journal    
DOI: 10.1159/000475777     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Kudo M: Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer 2015; 4: 39-50.
3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
4. Llovet JM, Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-1327.
5. Minami Y, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, et al: Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma: a single-center experience. Oncology 2015; 89(suppl 2):27-32.
6. Lencioni R, Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
7. Kudo M, Ueshima K, Kubo S, Sakamoto M, Tanaka M, Ikai I, Furuse J, et al: Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 revised version). Hepatol Res 2016; 46: 3-9.
8. Bruix J, Reig M, Sherman M: Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016; 150: 835-853.
9. Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, et al: Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology 2014; 87: 330-341.
10. Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, Kitai S, et al: Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma. Liver Cancer 2015; 4: 253-262.
11. Kudo M, Han G, Finn RS, Poon RT, Blanc JF, Yan L, Yang J, et al: Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology 2014; 60: 1697-1707.
12. Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, Davies N, et al: A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer 2013; 108: 1252-1259.
13. Zhou B, Yan Z, Liu R, Shi P, Qian S, Qu X, Zhu L, et al: Prospective study of transcatheter arterial chemoembolization (TACE) with ginsenoside Rg3 versus TACE alone for the treatment of patients with advanced hepatocellular carcinoma. Radiology 2016; 280: 630-639.
14. Terashima T, Yamashita T, Takata N, Nakagawa H, Toyama T, Arai K, Kitamura K, et al: Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib. Hepatol Res 2016; 46: 650-656.
15. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, et al: Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47: 2117-2127.
16. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, et al: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
17. Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, et al: Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 2015; 33: 172-179.
18. Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, et al: Ramucirumab versus placebo as secondline treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015; 16: 859-870.
19. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, et al: Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013; 31: 3509-3516.
20. Kudo M: Heterogeneity and subclassification of Barcelona Clinic Liver Cancer Stage B. Liver Cancer 2016; 5: 91-96.
21. Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, et al: Validation of Kinki Criteria, a modified substaging system, in patients with intermediate stage hepatocellular carcinoma. Dig Dis 2016; 34: 671-678.
22. Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, et al: Validation of a modified substaging system (Kinki Criteria) for patients with intermediate-stage hepatocellular carcinoma. Oncology 2015; 89(suppl 2):47-52.
23. Kudo M, Arizumi T, Ueshima K, Sakurai T, Kitano M, Nishida N: Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified Bolondi's Subclassification (Kinki Criteria). Dig Dis 2015; 33: 751-758.
24. Sakon M, Umeshita K, Nagano H, Eguchi H, Kishimoto S, Miyamoto A, Ohshima S, et al: Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. Arch Surg 2000; 135: 1456-1459.
25. Adachi E, Matsumata T, Nishizaki T, Hashimoto H, Tsuneyoshi M, Sugimachi K: Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis. Cancer 1993; 72: 3593-3598.